Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.
Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc AZN to jointly develop ...
It is increasingly recognized that galactose-deficient IgA in the glomerulus activates the alternative complement system and drives IgA nephropathy, including in the tubules and interstitium, leading ...
Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca (AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell ...
Otsuka reports positive Phase 3 two-year eGFR results on Voyxact: Tokyo Friday, July 3, 2026, 16:00 Hrs [IST] Otsuka Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Developmen ...
Medications that reduce blood pressure and improve glycemia may preserve kidney function over time despite initial eGFR dips, ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
MIT researchers have demonstrated that cell membrane composition directly influences EGFR activity, with elevated negatively ...
Combined treatment for EGFR-mutated NSCLC Your doctor may suggest an EGFR inhibitor, sometimes called a tyrosine kinase inhibitor (TKI), added to chemotherapy or a bispecific antibody — a treatment ...
Finding out you have epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) is a shock for anyone. You’ll have a lot to process and learn about your cancer and how your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results